Biogen Inc. BIIB.VI Stock
Biogen Inc. Price Chart
Biogen Inc. BIIB.VI Financial and Trading Overview
Biogen Inc. stock price | 189.25 EUR |
Previous Close | 269.6 EUR |
Open | 272 EUR |
Bid | 270 EUR x 0 |
Ask | 273.8 EUR x 0 |
Day's Range | 272 - 272 EUR |
52 Week Range | 183.2 - 305 EUR |
Volume | 0 EUR |
Avg. Volume | 9 EUR |
Market Cap | 40.6B EUR |
Beta (5Y Monthly) | 0.184507 |
PE Ratio (TTM) | 14.151926 |
EPS (TTM) | 7.42 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
BIIB.VI Valuation Measures
Enterprise Value | 40.58B EUR |
Trailing P/E | 14.151926 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 4.018465 |
Price/Book (mrq) | 2.854744 |
Enterprise Value/Revenue | 4.016 |
Enterprise Value/EBITDA | 12.015 |
Trading Information
Biogen Inc. Stock Price History
Beta (5Y Monthly) | 0.184507 |
52-Week Change | 39.45% |
S&P500 52-Week Change | 20.43% |
52 Week High | 305 EUR |
52 Week Low | 183.2 EUR |
50-Day Moving Average | 274.76 EUR |
200-Day Moving Average | 263.66 EUR |
BIIB.VI Share Statistics
Avg. Volume (3 month) | 9 EUR |
Avg. Daily Volume (10-Days) | 26 EUR |
Shares Outstanding | 144.74M |
Float | 144.32M |
Short Ratio | N/A |
% Held by Insiders | 0.68% |
% Held by Institutions | 89.89% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 30.98% |
Operating Margin (ttm) | 28.60% |
Gross Margin | 78.35% |
EBITDA Margin | 33.42% |
Management Effectiveness
Return on Assets (ttm) | 7.49% |
Return on Equity (ttm) | 25.03% |
Income Statement
Revenue (ttm) | 10.1B EUR |
Revenue Per Share (ttm) | 69.87 EUR |
Quarterly Revenue Growth (yoy) | -2.70% |
Gross Profit (ttm) | 7.9B EUR |
EBITDA | 3.38B EUR |
Net Income Avi to Common (ttm) | 3.13B EUR |
Diluted EPS (ttm) | 19.22 |
Quarterly Earnings Growth (yoy) | 27.70% |
Balance Sheet
Total Cash (mrq) | 5.04B EUR |
Total Cash Per Share (mrq) | 34.83 EUR |
Total Debt (mrq) | 6.61B EUR |
Total Debt/Equity (mrq) | 47.94 EUR |
Current Ratio (mrq) | 3.238 |
Book Value Per Share (mrq) | 95.28 |
Cash Flow Statement
Operating Cash Flow (ttm) | 1.68B EUR |
Levered Free Cash Flow (ttm) | 1.67B EUR |
Profile of Biogen Inc.
Country | Austria |
State | MA |
City | Cambridge |
Address | 225 Binney Street |
ZIP | 02142 |
Phone | 617 679 2000 |
Website | https://www.biogen.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 8725 |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Q&A For Biogen Inc. Stock
What is a current BIIB.VI stock price?
Biogen Inc. BIIB.VI stock price today per share is 189.25 EUR.
How to purchase Biogen Inc. stock?
You can buy BIIB.VI shares on the Vienna exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Biogen Inc.?
The stock symbol or ticker of Biogen Inc. is BIIB.VI.
Which industry does the Biogen Inc. company belong to?
The Biogen Inc. industry is Drug Manufacturers-General.
How many shares does Biogen Inc. have in circulation?
The max supply of Biogen Inc. shares is 145.36M.
What is Biogen Inc. Price to Earnings Ratio (PE Ratio)?
Biogen Inc. PE Ratio is 25.50539000 now.
What was Biogen Inc. earnings per share over the trailing 12 months (TTM)?
Biogen Inc. EPS is 7.42 EUR over the trailing 12 months.
Which sector does the Biogen Inc. company belong to?
The Biogen Inc. sector is Healthcare.